683 Capital Management’s Zevra Therapeutics ZVRA Stock Holding History

683 Capital Management’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Sell	855,000 -120,000	-12%	-$1.33M	0.6%	38
2026 Q1	$9.09M	Buy	975,000 +70,000	+8%	+$631K	0.47%	48
2025 Q4	$8.11M	Sell	905,000 -70,000	-7%	-$662K	0.35%	57
2025 Q3	$9.27M	Sell	975,000 -150,000	-13%	-$1.5M	0.48%	48
2025 Q2	$9.91M	Sell	1,125,000 -100,834	-8%	-$818K	0.65%	44
2025 Q1	$9.18M	Hold	1,225,834	–	–	0.63%	45
2024 Q4	$10.2M	Buy	1,225,834 +834	+0.1%	+$7.12K	0.63%	42
2024 Q3	$8.5M	Buy	1,225,000 +425,000	+53%	+$2.88M	0.65%	45
2024 Q2	$3.92M	Hold	800,000	–	–	0.3%	68
2024 Q1	$4.64M	Buy	800,000 +259,200	+48%	+$1.59M	0.34%	59
2023 Q4	$3.54M	Buy	+540,800	New	+$2.53M	0.29%	68

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

683 Capital Management's ZVRA Position: Q2 2026 in Review

683 Capital Management reduced its Zevra Therapeutics (ZVRA) stake by 12% in Q2 2026, selling an estimated $1.33M and leaving 855,000 shares worth $12.3M. The position accounts for 0.6% of the portfolio, ranked #38.

683 Capital Management first reported a position in ZVRA in Q4 2023 and has held it in 11 quarters since. 157 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

683 Capital Management held 855,000 shares of Zevra Therapeutics worth $12.3M as of Q2 2026.
683 Capital Management sold 120,000 Zevra Therapeutics shares in Q2 2026, an estimated $1.33M.
Zevra Therapeutics made up 0.6% of 683 Capital Management's portfolio in Q2 2026, its #38 holding.
683 Capital Management first reported a position in Zevra Therapeutics in Q4 2023 and has held it in 11 quarters since.
157 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.